Jwalit Vyas

  • Failed Paras bid a blow to Emami

    Failed Paras bid a blow to Emami

    Emami's unsuccessful attempt to acquire Paras Pharma may boost its short-term outlook, but the development will put pressure to identify other suitable targets to stay competitive in the segment.

    Zydus Wellness looks attractive

    Zydus Wellness looks attractive

    The stock of Zydus Wellness has more than doubled in the past nine months and is currently trading at a price-earning multiple of 43.

    Karuturi needs more funds to bloom

    Karuturi needs more funds to bloom

    Despite Karuturi’s stagnant earning per share (EPS) in the past few quarters, its stock price movement has been quite volatile.

    Pfizer deal shot in arm for Biocon

    Pfizer deal shot in arm for Biocon

    As per the deal, Biocon will conduct clinical development and regulatory filings while Pfizer will get the exclusive rights to market these products in most markets.

    Acquisitions double GCPL’s topline

    Acquisitions double GCPL’s topline

    The merger will help GCPL to reduce its dependence on soap products and also tackle high raw material cost caused by inflation in the soap segment.

    Bata India reaps the benefits of biz restructuring

    Bata India reaps the benefits of biz restructuring

    The scrip of Bata India, biggest footwear retailer in the country, hit an all-time high. Compared to a 16% gains in the benchmark Sensex, the company’s stock has more than doubled in the past one year.

  • No blogs yet have been written by the author, we’re sure the author will contribute one soon

Other useful Links


Follow us on


Download et app


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service